Nexstim has recently announced the completion of the Sitra financing arrangements and also disclosed the filing of the NBT system for the Treatment of Depression with the FDA. As we expected, both news updates show solid progress in the company, but the big news is still scheduled for Q2/2018 when the E-FIT trial reports. We reiterate both our target price of €0.93 and our OUTPERFORM recommendation.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid progress
Nexstim has recently announced the completion of the Sitra financing arrangements and also disclosed the filing of the NBT system for the Treatment of Depression with the FDA. As we expected, both news updates show solid progress in the company, but the big news is still scheduled for Q2/2018 when the E-FIT trial reports. We reiterate both our target price of €0.93 and our OUTPERFORM recommendation.